No disease recurrences after short course of neoadjuvant immunotherapy, according to follow-up

Дата публикации: 22-10-2026 19:20:05

A short course of neoadjuvant immunotherapy continues to show long-term outcomes in patients with locally advanced mismatch repair–deficient (dMMR) colon cancer. In the NICHE-2 study, none of the 111 patients in the primary efficacy population experienced disease recurrence, and all were alive at their most recent follow-up. The findings, now published in The Lancet, provide further evidence of the durability of response to neoadjuvant immunotherapy in this patient population.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Nivolumab-Ipilimumab for Gastric/Gastroesophageal Junction Adenocarcinoma	0	17.25	15-10-2026
2	Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma	0	5	09-07-2026
3	A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning	0	9.7	22-10-2026
4	Five-year survival outcomes with neoadjuvant therapy in melanoma demonstrate that neoadjuvant ICIs exceeded adjuvant benchmarks	0	13.78	13-10-2026
5	Perioperative durvalumab continues to show clinical benefit in patients with resectable stage IIA to IIIB NSCLC	0	9.27	17-09-2026
6	Hidden metastases reveal clues to colorectal cancer recurrence	3	7	09-07-2026
7	Moderna's cancer vaccine cuts melanoma recurrence risk in early trial: What we know	0	7.73	26-08-2026
8	Researchers show how leukemia cells 'hide' from treatment	0	9.92	23-10-2026
9	I survived colon cancer three times. Here's the unglamorous symptom I first noticed at 14... don't make the same mistake I did	0	8.08	16-10-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 8.19. Источник: medicalxpress.com.